Mid-January 2021 Annual Meeting Edition

January 2021 Annual Meeting Edition

Volume 7, Issue 2

This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.

Table of Contents

January 2021 Issue

There’s No Crime Like the Presents

Friday, January 15th, 2021
I hope you had a wonderful holiday season, and, although the climate seems to be working constantly against it, I hope some of you...

January 2021 Issue

FDA Approves Ponatinib for Chronic-Phase CML

Friday, January 15th, 2021
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...

Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma

Friday, January 15th, 2021
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...

Selinexor Combination Approved for Patients with Multiple Myeloma

Friday, January 15th, 2021
The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received...

Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS

Friday, January 15th, 2021
Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...

Registry Analysis Finds Patients With Hematologic Malignancies Are Highly Vulnerable to COVID-19

Friday, January 15th, 2021
In an analysis of data from the first 250 patients enrolled in the ASH Research Collaborative (ASH RC) COVID-19 Registry for Hematology, researchers found...
WIB_icon

Discontinuing Eculizumab is Safe and Feasible in Patients With Atypical Hemolytic Uremic Syndrome

Friday, January 15th, 2021
Discontinuation of anti-C5 agent eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome (aHUS), particularly in the 40% to 60% of...

Rethinking Autoimmune Neutropenia in Children

Friday, January 15th, 2021
Authors of a registry analysis published in Blood Advances have identified two distinct autoimmune neutropenia entities in children who present with apparent primary autoimmune...

Devimistat Receives FDA Fast Track Designation for AML

Friday, January 15th, 2021
The FDA has granted fast track designation to devimistat for the treatment of acute myeloid leukemia (AML), clearing its manufacturer, Rafael Pharmaceuticals, to begin...

NIH’s ACTIV Trial Suspends Enrollment of Critically Ill Patients With COVID-19

Friday, January 15th, 2021
The National Institutes of Health (NIH) announced that it is pausing enrollment of patients with severe COVID-19 in three trials that are evaluating anticoagulants...

January 2021 Issue

On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Friday, January 15th, 2021
Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia

Friday, January 15th, 2021
Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Friday, January 15th, 2021
Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Friday, January 15th, 2021
Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

Friday, January 15th, 2021
A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
On location

BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma

Friday, January 15th, 2021
In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
On location

Avatrombopag Demonstrates Efficacy in ITP, Regardless of Prior Treatment

Friday, January 15th, 2021
Treatment with the thrombopoietin receptor agonist (TPO-RA) avatrombopag led to durable platelet count responses in patients with immune thrombocytopenia (ITP), with responses among both...
On location

Big Ideas on Burnout: Trainees Propose System-Wide Solutions

Friday, January 15th, 2021
The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...
On location

Does High-Dose Methotrexate Protect the Central Nervous System in High-Risk DLBCL?

Friday, January 15th, 2021
A retrospective study found that treatment with high-dose methotrexate did not lower the risk of central nervous system (CNS) relapse in patients with high-risk...